Overview

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL).
Phase:
Phase 3
Details
Lead Sponsor:
Auris Medical, Inc.